TO.VA., self report, and QEEG. Both neurofeedback and carbamazepine showed the most effect in early treatment. Rogress continued after discontinuance of the drug.
We had an opportunity to study a patient who presented for evaluation for ADHD, referred by her psychotherapist, also managed by a neurologist for seizure disorder. Because of the seizure disorder and the patient's initial reluctance to take her prescribed anticonvulsant, carbamazepine, we elected to treat this patient primarily with neurofeedback, rather than with stimulant medication, which is contraindicated in untreated seizure disorder. However, after neurofeedback therapy began, the patient began taking an anticonvulsant, carbarnazepine, as recommended by her neurologist. Because the patient reached therapeutic carbamazepine levels, stopped the drug because of grogginess, then agreed to restart it, and then again discontinued it, we had the opportunity to study a naturalistic crossover effect. W e were able to measure the effects of neurofeedback therapy with and without carbamazepine on attentional testing and QEEG.
Interestingly, this patient also had established diagnoses of Borderline Personality Disorder and seizure disorder with features of partial complex seizure with interictal thought intrusions. The occurrence of these comorbidities, as well as the effect of carbamazepine on attentional disorders have been described, but not in a single case.
There appears to be an abundance of literature on the comorbidity of behavioral disorders, both organic and psychological. Andrulonis et al. (1980) report a high cooccurrence of borderline syndromes with other syndromes, such as Minimal Brain Dysfunction (MBD), a term used in the 1960's prior to the definition of Attention Deficit Disorder (ADD), and episodic dyscontrol. A follow-up study by Andrulonis, Glueck, Stroebel, and Vogel(l982) attempted to find and test subcategories for Bor-derline Personality Disorder which involved nonorganic borderlines, traumdepilepsy borderlines, and Attentional Deficitbarning Disorder borderlines. Using a four-way discriminant analysis function, significant differences were found between these groups, and a high number of patients in the organic group were found to exhibit episodic dyscontrol syndrome, MBD, or a disorder of the limbic system A study conducted of 286 individuals diagnosed with episodic dyscontrol syndrome found 94% t o present with either MBD, head injury, and/or epilepsy (Elliot, 1984) .
Andrulonis et al. (1980) report that borderline subjects often display attentional deficits as children. There appears to be a relationship between ADD and/or ADHD and head injury A self-report survey of high school and university students by Segalowitz and Lawson (1995) Tansey, 1984) .
attentional deficits and other disorders with anticonvulsants, such as carbamazepine, may be promising. The literature offers varied opinions of this. The use of anticonvulsant medication is sometimes required when the ADHD patient also presents with seizure disorder (Millichap, 1982) . Carbamazepine has also been used for rage outbursts. A study by Mattes (1990) found that patients exhibiting intermittent explosive disorder had significantly improved on carbamazepine, but that the patients with ADHD benefited more from propanolol.
Remschmidt (1976) proposed that carbamazepine would be beneficial to patients with behavioral disorders, including ADHD. A case study by Gay and Ryan (1992) report administering carbamazepine to a patient who acquired paroxysmal kinesigenic dystonia after receiving methylphenidate for posThere is some evidence that treating sible ADHD. The patient's symptoms ceased after carbamazepine was dispensed and recurred after discontinuance of it. Carbamazepine has also been applied as a treatment for hyperactivity. A study by Reid, Naylor, and Kay (1981) report improvements in five adult mentally handicapped patients with carbamazepine.
Regarding the question of what population will most likely react to treatment with carbamazepine, patients in whom hyperactivity was the primary problem seemed to respond to carbamazepine with lowered hyperactivity (Reid et al., 1981) . Carbamazepine has been proposed as one of the chosen drugs for use with borderlines. Furthermore, Andrulonis et al. (1980) hypothesized that anticonvulsants would best treat borderline patients with ADHD or learning disabilities, exhibiting episodic dyscontrol syndrome. Also, there has been a procedure proposed which attempts to identify which patients exhibiting a form of limbic system dysrhythmia would benefit from anticonvulsants. Ryback and Gardner (1991) administered procaine to patients with normal EEG' s. Many patients with ADHD who displayed a positive reaction to procaine, reported improvements in attention after carbamazepine.
Method
The subject is a 36-year-old female, diagnosed with temporally focused seizure disorder and an Axis I1 of Borderline Personality Disorder. She has had episodes of behavioral dyscontrol (i.e., destroying her medical records, throwing furniture around) which could be described as episodic dyscontrol syndrome, intermittent explosive disorder, or both. Under stress, the patient has reported severe psychotic thinking (i-e., fear of shooting others, belief she was a queen). The patient presented with attentional problems and was therefore administered the Wender Utah questionnaire and met criteria for childhood ADHD by achieving a score of at least 46 (Ward, Wender, & Reimherr, 1993) . She also met DSM-IV criteria for adult residual ADHD (either 6/9 inattention symptoms and/or 6/9 impulsivity-hyperactivity symptoms occurring at least most of the time with dysfunction in work or family life occurring most of the time). The patient was administered Dupuy and Greenberg's (1993) Test of Variables of Attention (T.O.V.A.). The patient's performance on the T -0.V.A. was compared to norms constituted for gender and age to the ninth decade (Greenberg & Woldman, 1993) . Test results were abnormal, h65, on omissions (t=81.4), reaction time (t=67.1), and variability (t=64.6). A self-report head injury history was also taken, and although the patient mentioned a few injuries, she did not meet criteria for significant mild traumatic brain injury (MTBI) by not meeting criteria of a Glascow Coma scale of 13-15.
A nineteen-channel Quantitative Electroencephalogram (QEEG) using Neurolex 24 (Lexicor, Boulder, CO) was taken under five conditions at a sampling rate of 128 Hz: eyes closed for two 200-300 second recordings; eyes open at rest and with listening, reading, and mental math for 100-150 seconds each. Artifact was rejected and the remaining epochs were analyzed by spectral averages in topographic maps across bands and visually inspected.
In addition, eyes-closed records were artifacted using high resolution graphics, analyzed, and compared to a normative data base (Thatcher, 1994a (Thatcher, , 1994b Thatcher, Walker, & Guidace 1987; Hudspeth, 1985; Hudspeth & Pribham, 1990 Boulder, CO), 4 electrodes (linked ears for reference, a common forehead ground and an active), 10/20 conductive paste, and skin preparing gel.
During the course of neurotherapy the patient agreed to begin carbamazepine 200 mg tid as recommended by her neurologist. After being on that medication for approximately 8 to 9 weeks, she stopped taking it because it made her drowsy, presumably as medication blood levels slowly increased. After a one week wash out period, T.O.V.A. and QEEG were repeated. The patient then agreed to resume carbamazepine at lower levels and began taking it at 200 mg bid.
Following stabilization with the drug for one week, T.O.V.A. and QEEG were again repeated. Subsequently at the end of therapy T.O.V.A. and QEEG were repeated, at which time the patient volunteered that she had secretly discontinued her medication several weeks after resuming it.
Throughout the course of neurofeedback therapy, the patient's score, an expression of the percentage of time she was able to exceed a 4 pv of SMR, was monitored as a measure of her success at training.
Results
Since neurofeedback, the patient reports Fallminter 1996improved adjustment in her professional and personal relationships. The patient has been able to hold a job, whereas she had difficulties with maintaining employment in the past. The patient has completed remedial classes at a community college and has enrolled in more classes, whereas in the past there was a history of dropping out. In therapy the patient has been reported by her psychologist as still being overly talkative, but more appropriate, keeping appointments more regularly than in the past, reporting fewer and more milder outbursts, and having a stable mood since the training started. score is consistent with attentional deficit, though improved. After reinstitution of carSessions 18 through 20, and then discontinued. bamazepine and months later back off carbamazepine, all four scales are normal and the test is no longer consistent with attentional deficit.
:s made by the subject over neurofeedbac ?ssions, the first 26 sessions done at CZ 'le following 4 at C4, with SMR rewa 1? inhibit of reward for movement, EM .d excess theta. The score for each sessio,-2s aepicted sequentially, score being defined as the percentage of time during the session the subject created SMR greater than 4 pv. & can be seen in Figure 1 , the subject generally improved over time. Between Sessions 7 and 8 the subject began carbamazepine 200 mg tid, and after Session 16 discontinued it. The subject was then studied by T .O.V.A. and QEEG after a 10 day wash-out period, and then agreed to resume carbamazepine a t 200 mg bid, which she continued for Figure 1 shows the prc: Table 2 displays 2 scores for alpha relative power across bands for 16 of the 19 international 10-20 sites pre and posttreatment. High frontal alpha relative power at baseline normalizes following neurofeedback, whether on or off carbamazepine. The posttreatment record is essentially the same for relative power on QEEG obtained aRer Session 17, after Session 18, and after Session 30, and only the record following Session 17 is shown.
Discussion
This case report illustrates the importance of integrating neurofeedback therapy with pharmacotherapy and psychotherapy. In this particular case, the relationships between each of the indicated therapies and each of the diagnostic formulations is important. The subject's clear lifetime diagnosis of attention deficit disorder is apparent from the childhood history (W ender Utah), the current symptoms (DSM-IV criteria for ADHD), and the subject's attentional performance (T.O.V.A.). The attentional problems prevented progress in psychotherapy issues around the subject' s personality disorder and lifetime abuse issues. This in turn led to a referral for ADHD evaluation and treatment. As part of that evaluation, stimulant medication was considered, but relatively contraindicated because of the presence of seizure disorder. The subject's reaction to anti-seizure medication was in turn colored by both her personality disorder in that she distrusted it, and by her ADHD in that usually effective doses made her groggy and impaired her attention even further. The seizure disorder treatment in turn seemed to have an impact on the personality disorder, in that the subject described intrusive homicidal impulses that disappeared on the carbamazepine, and she also described features of episodic anger dyscontrol that improved on carbamazepine. Furthermore, we found that carbamazepine enhanced her ability to meet neurofeedback goals, as well as improve her T.O.V.A. performance.
Thus, we began our treatment of her ADHD with neurofeedback alone. When she had developed trust in that process and some clinical improvement, she became willing to take the drug. Her progress accelerated, but then faltered because of sedation due to the drug. She discontinued that, affording us an opportunity to study her postneurofeedback, off carbamazepine. What we found was that QEEG changes were independent of carbamazepine, but followed neurofeedback, with substantial reduction in frontal alpha relative power. Attentional performance improved as a result of the neurofeedback treatment condition, with some improvement of T.O.V.A. Initially the patient's performance on the T -0,V.A. as well as her neurofeedback scores were enhanced by medication. As she continued with neurofeedback training, after 20 sessions she was able to discontin ,edication entirely, sustaining her imp ments in attentional performance and mc.
tabilization.
This case study illustrates the irnpcrtance of evaluating comorbidities of personality disorder and seizure disorder with attentional deficit disorder. The use of concurrent medication treatment initially enhanced the subject's ability to do neurofeedback. Following neurofeedback of the attentional enhancement type, there were substantial improvements in behavioral dyscontrol that had been thought to be due t o the seizure disorder or the personality disorder. Even though the patient was able t o stop medication and sustain these improvements, these improvements may be explained by her improved attention and focus as well as her enhanced ability to respond to psychotherapy.
